Arcturus Therapeutics to Present at October Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/7/2026

1. HUBS
2. WDC
3. SNDK
4. KVYO
5. APP

6. DASH
7. ZG
8. DOX
9. XYZ
10. PAYC

Get Alerts ARCT Hot Sheet

Price: $6.08 --0%

Overall Analyst Rating:
SELL (= Flat)

Dividend Yield: 6%

Join SI Premium – FREE

SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced that Joseph Payne will present at four investor conferences in October: Microcap Conference, Ladenburg Thalmann 4th Annual Healthcare Conference, LEERINK Partners Roundtable Series – Rare Disease & Oncology, and Chardan 2nd Annual Genetic Medicine Conference. In addition, Arcturus will be present at the invitation-only JLABS CEO Summit where Melinda Richter, Global Head, Johnson & Johnson Innovation, JLABS, will host a fireside chat with Arcturus CEO Joseph Payne.

The Microcap Conference

Presenter:	Joseph Payne, President & CEO
Date:	Monday, October 1
Time:	4pm Eastern Time
Location:	JW Marriott Essex House in New York City

Ladenburg Thalmann 4th Annual Healthcare Conference

Presenter:	Joseph Payne, President & CEO
Date:	Tuesday, October 2
Time:	8:30am Eastern Time
Location:	Sofitel New York Hotel

LEERINK Partners Roundtable Series – Rare Disease & Oncology

Presenter:	Joseph Payne, President & CEO
Date:	Tuesday, October 2
Time:	4:00pm Eastern Time
Location:	Lotte New York Palace Hotel

Chardan 2nd Annual Genetic Medicine Conference

Presenter:	Joseph Payne, President & CEO
Date:	Tuesday, October 9
Time:	10:30am Eastern Time
Location:	Westin Grand Central Hotel, New York City

About Arcturus Therapeutics Ltd.Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Ltd. (NASDAQ: ARCT) is an RNA medicines company with enabling technologies – UNA Oligomer chemistry and LUNAR® lipid-mediated delivery. Arcturus’ diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis, and vaccines. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. Arcturus owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology including UNA Oligomers, which are covered by its extensive patent portfolio (140 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ proprietary UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. Arcturus’ commitment to the development of novel RNA therapeutics has led to partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG and Cystic Fibrosis Foundation Therapeutics Inc. For more information, visit www.Arcturusrx.com, the content of which is not incorporated herein by reference.

Arcturus ContactNeda SafarzadehArcturus Therapeutics(858) 900-2682[email protected]

Arcturus Investor ContactMichael WoodLifeSci Advisors LLC(646) 597-6983[email protected]